ResearcherTaipei Medical UniversityNo recent work listed
Chi‐Tai Yeh
Matched on ORCID iD 0000-0001-5189-9755; OpenAlex author ID A5006041425. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper
Papers 3
- Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP14/TGF-β axis, which is inhibited by 4-ac… Co-author DOI 10.1016/j.phymed.2022.154062↗
- Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. Last author DOI 10.3390/cells9040911↗
- The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity. Co-author DOI 10.1007/s10585-018-9919-5↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shiue‐Wei Lai · 3 shared papers, 2018–2022 · strength 0.36
- Paper Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP1… DOI 10.1016/j.phymed.2022.154062↗
- Paper Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancr… DOI 10.3390/cells9040911↗
- Paper The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and … DOI 10.1007/s10585-018-9919-5↗
- Tsu-Yi Chao · 2 shared papers, 2018–2020 · strength 0.22
- Paper Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancr… DOI 10.3390/cells9040911↗
- Paper The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and … DOI 10.1007/s10585-018-9919-5↗
- Chung‐Ze Wu · 1 shared paper, 2022 · strength 0.15
- Jin‐Shuen Chen · 1 shared paper, 2022 · strength 0.15
- Alexander T.H. Wu · 1 shared paper, 2020 · strength 0.13
- Wen‐Chiuan Tsai · 1 shared paper, 2018 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.